Parkinson's Disease Re-envisioned as a Network Disorder

Parkinson's disease is a complex and currently incurable brain disorder. It usually begins with subtle problems, such as sleep disturbances, and eventually affects movement and thinking. New research suggests that many of these diverse symptoms arise from a malfunction in a specific brain system known as the somato-cognitive action network, or SCAN. Scientists believe this network coordinates bodily arousal, internal organ function, and whole-body movement with a person's motivation. To test this hypothesis, researchers compiled a large clinical dataset using brain scans from 863 people.

Analysis of resting-state brain activity revealed that key brain structures damaged in Parkinson's are uniquely linked to the SCAN, rather than to areas controlling specific body parts. Most importantly, the disease is defined by hyperconnectivity, which is excessive communication, between the SCAN and these deep-brain structures. When patients received effective treatments, this hyperconnectivity decreased. Furthermore, targeting the SCAN with non-invasive brain stimulation doubled the treatment benefit. These findings suggest that SCAN hyperconnectivity is central to Parkinson's disease and that reducing it is a common sign of successful therapy.

Parkinson's disease is traditionally viewed as a movement disorder, but it actually disrupts the entire body system. Motor symptoms include shaky hands, rigid muscles, slow movement, and difficulties walking. The disease also involves many non-motor problems, such as constipation, low blood pressure, sleep disturbances, and a loss of motivation and planning ability. Notably, cognitive factors can influence motor symptoms. For example, walking may deteriorate under stress but improve when listening to music.

The primary biological cause of Parkinson's is the death of dopamine-producing neurons in a deep brain region called the substantia nigra. This damage affects a critical brain circuit involving the cortex, basal ganglia, and thalamus. Initially, this circuit responds well to medications that replace dopamine, such as levodopa. However, over many years, these drugs often become less effective. This decline leads doctors to use additional brain stimulation therapies.

The U.S. Food and Drug Administration has approved deep brain stimulation, or DBS, for several Parkinson's motor symptoms. Electrodes can be placed in the subthalamic nucleus or the internal part of the globus pallidus. DBS can also target a part of the thalamus called the ventral intermediate nucleus to treat tremor. While effective, DBS is invasive, costly, and can sometimes impair thinking. Non-invasive methods like transcranial magnetic stimulation show potential but have lacked precise targets on the brain's surface.

The widespread, whole-body nature of Parkinson's symptoms has been historically hard to explain by problems in brain regions that control just the hand or foot. The recent discovery of the SCAN provided a new framework. This network is intertwined with classic motor areas and is responsible for coordinating whole-body action, arousal, and automatic bodily functions. Since Parkinson's symptoms affect the whole body, scientists hypothesized that SCAN dysfunction might be a major contributor.

To investigate, researchers built a comprehensive dataset. They used advanced brain imaging to map connections in patients with Parkinson's and healthy individuals. For comparison, they included people with other movement disorders: essential tremor, dystonia, and amyotrophic lateral sclerosis. To understand how treatments work, they followed six groups of patients undergoing different therapies: DBS, adaptive DBS, TMS, MRI-guided focused ultrasound, and levodopa.

Analyses of functional brain connectivity confirmed the distinct pattern of the SCAN in all participants. The crucial discovery was that six deep-brain structures central to Parkinson's—the substantia nigra, subthalamic nucleus, ventral intermediate nucleus, globus pallidus, the external part of the globus pallidus, and the putamen—were all more strongly connected to the SCAN than to regions controlling specific body parts or other functional networks. This indicated that the critical cortico–basal ganglia–thalamic circuit in Parkinson's is preferentially wired into the SCAN.

Researchers found that the connectivity between the SCAN and the six key deep-brain structures was significantly elevated in Parkinson's patients compared to healthy people. This SCAN hyperconnectivity was confirmed across separate datasets. It coincided with an expansion of the SCAN's influence in the deep brain. Importantly, this excessive connectivity was specific to the SCAN and was not seen in other major brain networks. It was also not a general feature of all movement disorders, as it was absent in patients with essential tremor, dystonia, or amyotrophic lateral sclerosis.

Furthermore, the strength of the connection from the deep brain to the SCAN was closely linked to the severity of a patient's motor symptoms, cognitive test scores, anxiety, and depression.

Analyses showed that the most effective locations for DBS electrodes, or "sweet spots," within the subthalamic nucleus, globus pallidus, and ventral intermediate nucleus were more strongly connected with the SCAN than with primary motor regions for specific body parts.

Direct evidence came from recordings taken directly from the brain's surface in 17 Parkinson's patients during subthalamic nucleus-DBS surgery. When the motor part of the subthalamic nucleus was stimulated, the strongest responses on the cortical surface were recorded in areas defined as part of the SCAN, not in areas controlling specific effectors. The average electrical response in the SCAN was significantly larger than in the area controlling the mouth. The first cortical signal, which corresponds to activating the direct pathway from the cortex to the subthalamic nucleus, was also significantly larger in the SCAN.

In patients receiving adaptive DBS, the cortical electrodes used to control the stimulation were positioned closer to the center of a key SCAN node than to hand or foot motor regions. Together, this connectivity and direct recording data indicate that effective DBS works by modulating the SCAN circuit.

The central finding of SCAN hyperconnectivity led researchers to propose that reducing this excessive communication might be a common mechanism behind successful treatments. They tracked connectivity changes in patients receiving different therapies.

In patients undergoing DBS while in an MRI scanner, effective subthalamic nucleus-DBS significantly reduced the hyperconnectivity between the SCAN and the stimulated brain node. Similarly, in patients receiving MRI-guided focused ultrasound treatment for tremor, clinical benefit was greater when the ultrasound target was closer to a thalamic "SCAN sweet spot." Reducing the distance to this spot by just 1 millimeter improved tremor scores by approximately 3.5%.

A levodopa challenge test in 21 Parkinson's patients showed that the medication also normalized the hyperconnectivity between the SCAN and the deep brain. The amount of connectivity reduction correlated with each individual's motor improvement.

Given the SCAN's representation on the brain's surface, researchers tested whether targeting it could improve non-invasive transcranial magnetic stimulation. In a group of 36 Parkinson's patients, targeting the probabilistically defined SCAN region with TMS was compared to targeting the standard hand motor region.

Targeting the SCAN doubled the treatment efficacy. Patients who received SCAN-targeted TMS showed significantly greater improvement in walking speed and step length compared to those receiving standard treatment. This demonstrates that using a functionally defined cortical target based on the SCAN offers a highly effective method for non-invasive brain stimulation in Parkinson's.

This study reframes Parkinson's disease as a disorder of the somato-cognitive action network. The findings demonstrate that key deep-brain structures degenerating in Parkinson's are functionally anchored to the SCAN. The disease is characterized by hyperconnectivity within this SCAN-subcortex circuit, which correlates with the severity of various symptoms.

A key discovery is that successful therapeutic interventions—whether dopaminergic medication, deep brain stimulation, focused ultrasound, or transcranial magnetic stimulation—all converge on normalizing this pathological hyperconnectivity. The SCAN provides a unified functional target for both invasive and non-invasive treatments.

For invasive therapies like DBS and MRI-guided focused ultrasound, targeting functionally defined SCAN nodes within traditional anatomical targets could improve outcomes and allow for more personalized treatment. For non-invasive approaches like transcranial magnetic stimulation, the cortical SCAN offers a precise and highly effective target, potentially doubling treatment benefits.

This SCAN-centric model explains Parkinson's whole-body motor, autonomic, arousal, and motivational symptoms through the dysfunction of a single, integrative network. It moves beyond a focus on specific body parts to a systems-level understanding, opening new avenues for mechanism-based therapies across the full spectrum of Parkinson's disease symptoms.